Hoechst Aktiengesellschaft

Karl Rudolphi

Ulrich Gebert

John J Grome

Elisabeth Defossa

Uwe Heinelt

Harald Furrer

Hans-Peter Schubert

Hiristo Anagnostopulos

Erhard Wolf

Hildegard Nimmesgern

Barbara Kittner

Theophylline derivatives having at least one ether function in the structurally modified methyl radical in the 1-position that are useful in the treatment and prophylaxis of states of shock, new xanthine compounds having this substitution pattern, and processes for their preparation.

Use of theophylline derivatives for the treatment and prophylaxis of states of shock, novel xanthine compounds and processes for their preparation

The invention relates to a composition which is a pharmaceutical combination preparation comprising a compound which has an acetylcholinesterase-inhibitory action or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level, wherein the combination preparation is suitable for the treatment of dementia. The invention further relates to a process for the production of the combination preparation. The invention additionally relates to a process for treating patients in need of suitable therapy with the combination preparation.

Combination preparation for use in dementia

Compounds of the formula I, ##STR1## in which one of the radicals R.sup.1 and R.sup.3 is an alkynol residue of the formula Ia or Ib ##STR2## are suitable for producing pharmaceuticals having a neuroprotective effect.

Xanthine compounds having terminally animated alkynol side chains

R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthine, a process for its preparation, and pharmaceuticals which contain this compound and which are suitable, in particular, for the prophylaxis and treatment of cerebral vascular disorders.

R-(-)1-(5-hydroxyhexyl)-3-methyl-7-propylxanthine, a process for its

The use of xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas (CCT) The use of xanthine derivatives of the formula I ##STR1## and of their physiologically tolerable salts, in which R.sup.1 is oxoalkyl, hydroxyalkyl or alkyl, R.sup.2 is hydrogen or alkyl and R.sup.3 is hydrogen, alkyl, oxoalkyl or an alkyl having up to 6 carbon atoms, whose carbon chain is interrupted by an oxygen atom, for the production of pharmaceuticals for the treatment of disorders which can occur after cranio-cerebral traumas is described.

Growing community of inventors

Mainz, Germany

Karl Rudolphi